A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Active, not recruiting · Phase 3 · NCT04194944
Conditions: Non-Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $45,118
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 261
About the trial
- Sponsor
- Eli Lilly and Company (with Loxo Oncology, Inc.)
- Tested
- Selpercatinib (drug), Carboplatin (drug), Cisplatin (drug), Pemetrexed (drug), Pembrolizumab (drug)
- Dates
- Started 2020-02-17; completion 2030-06
- Results posted
- Yes
The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
From ClinicalTrials.gov, last updated 2026-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $45,118 in research payments for this study in 2025 (16 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $45,118
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.